{
  "content": "Diagnosis\n\t1. Papillary renal cell carcinoma type 1, FH deficient\n\t\tInitial diagnosis January 2023\n\t\tpT3aN0M1 at presentation\n\t\tLower pole right kidney primary with pleural and pulmonary metastases\n\n\tTreatment aim\n\tPalliative\n\n\tSummary of completed treatment\n\tSurgery\n\t15 Jan 2023 Right radical nephrectomy\n\tComplications: Post-operative ileus requiring prolonged admission\n\n\tSystemic therapy\n\t1. Cabozantinib 60mg OD commenced March 2023\n\t2. Dose reduction to 40mg OD April 2023 due to grade 3 palmar-plantar syndrome\n\t3. Current dose 40mg OD with stable disease\n\n\tClinical studies\n\tNot eligible for current trials due to FH mutation status\n\n\tCurrent disease status\n\tStable disease on imaging\n\tLatest CT thorax/abdomen/pelvis 15 May 2024 shows:\n\t- Stable pleural deposits largest 2.2cm (previously 2.3cm)\n\t- Stable pulmonary nodules, largest 8mm right lower lobe\n\t- No new sites of disease\n\n\tCurrent issues\n\t1. Grade 1 palmar-plantar syndrome\n\t2. Stable renal function\n\n\tSummary of consultation\n\tReviewed today in medical oncology clinic. Tolerating reduced dose Cabozantinib well with improvement in hand-foot syndrome following previous dose reduction. Latest imaging shows continued disease control. Blood pressure well controlled on amlodipine. Renal function stable with creatinine 132 (baseline 128).\n\n\tFurther investigations\n\tRepeat CT thorax/abdomen/pelvis in 12 weeks\n\tRoutine blood tests including TFTs in 4 weeks\n\n\tMedication prescribed\n\tContinue Cabozantinib 40mg OD\n\n\tFollow up\n\tMedical oncology review in 4 weeks with blood results\n\tRepeat imaging review in 12 weeks",
  "output": {
    "primary_cancer": {
      "site": "kidney, right lower pole",
      "year": 2023,
      "month": 1,
      "metastases": "pleural deposits and pulmonary nodules",
      "tnm_stage": "pT3aN0M1",
      "other_stage": "Stage III",
      "histopathology_status": "papillary renal cell carcinoma type 1",
      "biomarker_status": "FH deficient",
      "cancer_timeline": [
        {
          "type": "treatment_surgery",
          "value": "Right radical nephrectomy complicated by post-operative ileus",
          "year": 2023,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started Cabozantinib 60mg daily",
          "year": 2023,
          "month": 3
        },
        {
          "type": "treatment_systemic_change",
          "value": "Cabozantinib dose reduced to 40mg daily due to grade 3 palmar-plantar syndrome",
          "year": 2023,
          "month": 4
        },
        {
          "type": "anatomical_finding",
          "value": "CT thorax/abdomen/pelvis shows stable pleural deposits (largest 2.2cm) and pulmonary nodules (largest 8mm)",
          "year": 2024,
          "month": 5
        }
      ]
    },
    "patient_facts": [
      {
        "type": "investigation_finding",
        "value": "Creatinine 132 (baseline 128)"
      },
      {
        "type": "current_symptom",
        "value": "Grade 1 palmar-plantar syndrome"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Metastatic papillary renal cell carcinoma with stable disease on reduced dose Cabozantinib"
      },
      {
        "type": "latest_treatment_response",
        "value": "Stable disease on imaging with no new sites of disease"
      },
      {
        "type": "latest_treatment_toxicity",
        "value": "Grade 1 palmar-plantar syndrome, improved following previous dose reduction"
      },
      {
        "type": "update_to_treatment",
        "value": "Continue Cabozantinib 40mg daily"
      },
      {
        "type": "planned_investigation",
        "value": "CT thorax/abdomen/pelvis in 12 weeks, blood tests including TFTs in 4 weeks"
      },
      {
        "type": "follow_up_referral",
        "value": "Medical oncology review in 4 weeks with blood results"
      }
    ]
  }
}